Your session is about to expire
What is Innohep
TinzaparinThe Generic name of this drug
Treatment SummaryTinzaparin is an anticoagulant and antithrombotic drug used to prevent clotting. It is produced by breaking down a more complex form of heparin, a natural substance found in the intestines of pigs. Tinzaparin binds to a protein called antithrombin III to stop the action of a certain enzyme called factor Xa. It is a low molecular weight heparin, meaning it is shorter than other types of heparin and is less effective at stopping the action of factor IIa. Tinzaparin must be injected into the muscle or under the skin.
Innohepis the brand name
Innohep Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Innohep
Tinzaparin
2008
2
Approved as Treatment by the FDA
Tinzaparin, otherwise known as Innohep, is approved by the FDA for 9 uses including General Surgery and Clotting .General Surgery
Clotting
prophylaxis of Clotting
indwelling intravenous lines
Deep Vein Thrombosis
Used to treat Deep Vein Thrombosis in combination with Warfarin
Orthopedic Procedures
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Used to treat Pulmonary embolism, Deep vein thrombosis in combination with Warfarin
Prophylaxis of Venous Thromboembolic Events
Effectiveness
How Innohep Affects PatientsTinzaparin is an anticoagulant that works by blocking the formation of blood clots. It is different from heparin, as it has higher activity against Factor Xa than Factor IIa. Routine monitoring of tinzaparin levels is not recommended. However, it may be monitored in certain cases, such as pregnancy or renal dysfunction. Tinzaparin should not be used in patients with a creatinine clearance below 20 mL/min, as it can cause serious side effects. However, it can be safely used in those with a creatinine clearance between 20-30 mL/min, making
How Innohep works in the bodyTinzaparin works by preventing the formation of a clot. It does this by binding to a protein in the blood called antithrombin III and forming a complex with it. This complex accelerates the inhibition of factor Xa, which stops the production of thrombin. Without thrombin, fibrinogen cannot be converted to fibrin, which is needed to form clots. Tinzaparin must be given intravenously due to the increased risk of hematoma if injected intramuscularly.
When to interrupt dosage
The advised dosage of Innohep is contingent upon the diagnosed affliction, including prophylaxis of Clotting, Pulmonary Embolism and Deep Vein Thrombosis. The measure of dosage fluctuates as per the administration approach outlined in the table below.Condition
Dosage
Administration
General Surgery
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Deep Vein Thrombosis
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Clotting
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Deep Vein Thrombosis (DVT)
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Pulmonary Embolism
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Prophylaxis of Venous Thromboembolic Events
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Orthopedic Procedures
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
prophylaxis of Clotting
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
indwelling intravenous lines
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Warnings
Innohep has five contraindications, thus it should not be combined with the circumstances featured in the following table.Innohep ContraindicationsCondition
Risk Level
Notes
history of thrombocytopenia caused by Heparin
Do Not Combine
Pulse Frequency
Do Not Combine
Thrombocytopenia caused by Heparin
Do Not Combine
Hemorrhage
Do Not Combine
Pulse Frequency
Do Not Combine
Common Innohep Drug Interactions
Drug Name
Risk Level
Description
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Tinzaparin.
Andexanet alfa
Major
The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Tinzaparin.
Anti-inhibitor coagulant complex
Major
The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Tinzaparin.
Antihemophilic factor (recombinant), PEGylated
Major
The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Tinzaparin.
Antihemophilic factor human
Major
The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Tinzaparin.
Innohep Toxicity & Overdose RiskTaking LMWH for an extended period of time can lead to osteoporosis, bleeding, hair loss, and HIT. Tinzaparin has been shown to be safe and not cause any toxic effects in mice, rats, and dogs even at doses up to 5mg/kg.
Innohep Novel Uses: Which Conditions Have a Clinical Trial Featuring Innohep?
48 active clinical trials are investigating the potential of Innohep to provide indwelling intravenous lines, prophylaxis of Clotting and Prophylaxis of Venous Thromboembolic Events for treatment of various conditions.Condition
Clinical Trials
Trial Phases
Orthopedic Procedures
5 Actively Recruiting
Phase 1, Not Applicable, Phase 4
Clotting
0 Actively Recruiting
Deep Vein Thrombosis (DVT)
27 Actively Recruiting
Phase 4, Phase 3, Not Applicable, Early Phase 1, Phase 1, Phase 2
Deep Vein Thrombosis
17 Actively Recruiting
Phase 4, Phase 3, Not Applicable, Phase 1, Phase 2
Prophylaxis of Venous Thromboembolic Events
0 Actively Recruiting
prophylaxis of Clotting
0 Actively Recruiting
General Surgery
1 Actively Recruiting
Not Applicable
indwelling intravenous lines
0 Actively Recruiting
Pulmonary Embolism
0 Actively Recruiting
Innohep Reviews: What are patients saying about Innohep?
4Patient Review
12/12/20092.7Patient Review
1/29/2014 I was disappointed that this didn't work more quickly. The swelling in my arm, forearm, and hand went down gradually over the course of three weeks. It has been effective in preventing another clot from occurring, though.
2.7Patient Review
5/18/2014 The daily shots are a bit of a pain, but they're nothing compared to the side effects of Xarelto.
Patient Q&A Section about innohep
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is innohep the same as heparin?
"INNOHEP® (tinzaparin) and other low molecular weight heparins differ in manufacturing process, molecular weight distribution, anti-Xa and anti-IIa activities, units, and dosage, so they cannot be used interchangeably (unit for unit). Each of these medications has its own instructions for use."
Answered by AI
Where do you inject innohep when pregnant?
"It is safe to inject LMWH into the abdomen, upper outer side of the thigh, or upper outer part of the buttock while pregnant. If you have had surgery (such as a caesarean section), avoid injecting too close to the wound or bandages."
Answered by AI
What is innohep used for?
"Innohep prevents clotting and allows normal blood flow through the arteries and veins. It is used to prevent blood clots in adults before and after an operation, or in those who have an increased risk of developing them due to an acute illness or limited mobility."
Answered by AI
How is innohep given?
"The medication should be injected into the skin of the stomach or abdomen, as directed by a doctor. It is usually injected once per day. Do not inject it into a muscle. The dosage and length of treatment depend on the person's medical condition, weight, and response to treatment. It is important to use this medication regularly to get the most benefit from it."
Answered by AI